“Chris Brough has been an integral figure at Dispersol since its inception,” said Dr. Edward Rudnick, CEO of Dispersol Applied Sciences. “Being co-inventor and innovation chief in our core Kinetisol expertise, Chris has built our Dispersol Know-How Heart.
At DTC, we are truly fully embedded in the design, manufacturing and programming of our proprietary manufacturing tools His engineering, scientific and enterprise acumen has been instrumental in the progress of each company, and has been instrumental in the evolution of expertise from a laboratory machine to a commercial engine.
It is with great pleasure that we have the Chief Knowledgeable Officer By selling, we acknowledge their many past contributions and their important position in our future progress.
“It’s an honor to be Dispersol’s first Chief Technical Officer,” said Chris Brau. “I set out to take advantage of the new capabilities created at DTC to keep Dispersol at the slicing fringe of amorphous stable dispersion drug development.
Dispersol has grown into a late scientific stage pharmaceutical firm that is no longer in its wares. I and my group will continue our work to ensure a profitable future for the corporate and its pipeline.”
Dr. Brough is the lead developer of KinetiSol. In 1999, he started a plastics recycling firm, based primarily on a novel patent course he had invented, a precursor to Kinetisol. That firm was acquired by IntegriCo Composites in 2005.
As IntegriCo’s VP of Engineering and Product Development, Chris led the organization and deployment of his expertise at IntegriCo and across multiple plastics business peers.
In 2006, Chris met Dave Miller and the two investigated expertise for a new software, creating stable amorphous dispersions of prescribed drugs. Upon profitable results, Chris redesigned equipment for pharmaceutical GMP use and was co-founder of Dispersol Applied Sciences in 2007.
Chris holds a BS and MS in Mechanical Engineering with an MBA from Brigham Younger College and a PhD in Pharmaceuticals. Texas College in Austin. Their analysis focused on the drug solubility enhancement of the kinetisol course and the abuse deterrent formulation function.
About Dispersol Applied Sciences
Dispersol is a clinical-stage drug growth firm focused on developing new treatments for sufferers using its proprietary Kinetisol® expertise platform. Kinetisol is confirmed to be able to create novel therapeutics to deliver specific scientific benefits to patients with poorly bioavailable drug.
The platform allows for drug development paths for patients when other options fail to distinguish. Active applications of dispersol include DST-0509 entering Section 3 for iron overload dysfunction, DST-2970 in Section 2 of refractory metastatic prostate cancer and DST-8294 for the treatment of clotting problems. Additional pre-stage applications include DST-0058 and DST-5407 for most cancers of idiopathic pulmonary fibrosis and non-squamous non-small cell lung, respectively.